| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 105 | 2023 | 301 | 24.400 |
Why?
|
| Gastrointestinal Hemorrhage | 73 | 2023 | 185 | 19.130 |
Why?
|
| Liver Diseases | 31 | 2022 | 193 | 11.870 |
Why?
|
| Liver | 78 | 2022 | 1118 | 10.510 |
Why?
|
| Esophageal and Gastric Varices | 27 | 2023 | 47 | 9.710 |
Why?
|
| Hypertension, Portal | 31 | 2023 | 53 | 9.240 |
Why?
|
| Gastroenterology | 21 | 2022 | 98 | 8.590 |
Why?
|
| Chemical and Drug Induced Liver Injury | 25 | 2022 | 131 | 8.130 |
Why?
|
| Hepatic Stellate Cells | 24 | 2022 | 53 | 7.310 |
Why?
|
| Endoscopy, Gastrointestinal | 30 | 2021 | 171 | 6.670 |
Why?
|
| Hepatic Encephalopathy | 18 | 2022 | 25 | 6.000 |
Why?
|
| End Stage Liver Disease | 9 | 2022 | 60 | 4.770 |
Why?
|
| Humans | 329 | 2023 | 68618 | 4.720 |
Why?
|
| Liver Function Tests | 19 | 2021 | 114 | 4.060 |
Why?
|
| Colonoscopy | 25 | 2019 | 156 | 4.020 |
Why?
|
| Anemia, Iron-Deficiency | 12 | 2020 | 34 | 3.970 |
Why?
|
| Nitric Oxide Synthase Type III | 9 | 2022 | 102 | 3.700 |
Why?
|
| Male | 191 | 2022 | 37321 | 3.500 |
Why?
|
| Hospitalization | 18 | 2023 | 978 | 3.450 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 13 | 2022 | 22 | 3.410 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 11 | 2022 | 87 | 3.350 |
Why?
|
| Hepatitis C, Chronic | 15 | 2021 | 86 | 3.350 |
Why?
|
| Endothelial Cells | 12 | 2022 | 384 | 3.340 |
Why?
|
| Colonography, Computed Tomographic | 13 | 2012 | 23 | 3.240 |
Why?
|
| Liver Neoplasms | 8 | 2022 | 334 | 3.170 |
Why?
|
| Biopsy | 17 | 2022 | 540 | 3.170 |
Why?
|
| Endothelin-1 | 15 | 2022 | 122 | 2.970 |
Why?
|
| Wound Healing | 17 | 2014 | 260 | 2.960 |
Why?
|
| Female | 154 | 2022 | 38074 | 2.920 |
Why?
|
| Middle Aged | 117 | 2022 | 21147 | 2.880 |
Why?
|
| Gastrointestinal Diseases | 14 | 2020 | 107 | 2.860 |
Why?
|
| Inpatients | 6 | 2022 | 208 | 2.820 |
Why?
|
| Liver Cirrhosis, Experimental | 16 | 2020 | 20 | 2.770 |
Why?
|
| Retrospective Studies | 54 | 2023 | 7277 | 2.630 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2023 | 189 | 2.620 |
Why?
|
| Colonic Polyps | 10 | 2012 | 63 | 2.590 |
Why?
|
| Antiviral Agents | 10 | 2021 | 211 | 2.570 |
Why?
|
| Anticoagulants | 11 | 2022 | 356 | 2.550 |
Why?
|
| Actins | 12 | 2022 | 249 | 2.540 |
Why?
|
| Stomach Diseases | 4 | 2021 | 22 | 2.540 |
Why?
|
| Ammonia | 6 | 2020 | 28 | 2.520 |
Why?
|
| Occult Blood | 15 | 2014 | 48 | 2.510 |
Why?
|
| Gastrointestinal Agents | 7 | 2022 | 51 | 2.390 |
Why?
|
| Colorectal Neoplasms | 16 | 2018 | 561 | 2.350 |
Why?
|
| Surface-Active Agents | 5 | 2016 | 57 | 2.320 |
Why?
|
| Polyethylene Glycols | 6 | 2015 | 149 | 2.250 |
Why?
|
| Aged | 78 | 2021 | 14862 | 2.240 |
Why?
|
| Nitric Oxide | 22 | 2022 | 382 | 2.230 |
Why?
|
| Liver Transplantation | 12 | 2021 | 400 | 2.200 |
Why?
|
| Biomedical Research | 7 | 2021 | 310 | 2.150 |
Why?
|
| Vasoconstrictor Agents | 12 | 2020 | 107 | 2.140 |
Why?
|
| Hepacivirus | 7 | 2021 | 90 | 2.100 |
Why?
|
| Adult | 87 | 2022 | 21403 | 2.090 |
Why?
|
| Actin Cytoskeleton | 4 | 2022 | 37 | 2.030 |
Why?
|
| Varicose Veins | 5 | 2023 | 11 | 2.030 |
Why?
|
| Hepatitis C | 9 | 2021 | 114 | 2.000 |
Why?
|
| Rats | 55 | 2022 | 5300 | 1.990 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2021 | 163 | 1.950 |
Why?
|
| Rats, Sprague-Dawley | 41 | 2020 | 2083 | 1.940 |
Why?
|
| Signal Transduction | 24 | 2022 | 2689 | 1.920 |
Why?
|
| Iron | 4 | 2020 | 197 | 1.920 |
Why?
|
| Lactulose | 4 | 2022 | 13 | 1.910 |
Why?
|
| Animals | 88 | 2022 | 20881 | 1.880 |
Why?
|
| Colonic Diseases | 7 | 2019 | 36 | 1.850 |
Why?
|
| Trans-Activators | 4 | 2020 | 237 | 1.840 |
Why?
|
| Endoscopy | 8 | 2021 | 464 | 1.720 |
Why?
|
| Hospital Mortality | 9 | 2020 | 384 | 1.710 |
Why?
|
| Ascites | 8 | 2023 | 38 | 1.700 |
Why?
|
| Hemostasis, Endoscopic | 7 | 2015 | 17 | 1.660 |
Why?
|
| Cohort Studies | 26 | 2020 | 2358 | 1.650 |
Why?
|
| Internal Medicine | 5 | 2020 | 118 | 1.620 |
Why?
|
| Cells, Cultured | 32 | 2022 | 2673 | 1.620 |
Why?
|
| Hemoglobins | 6 | 2020 | 120 | 1.620 |
Why?
|
| Interferon-gamma | 9 | 2012 | 241 | 1.560 |
Why?
|
| Primary Health Care | 8 | 2021 | 703 | 1.560 |
Why?
|
| Esophagitis | 4 | 2015 | 45 | 1.560 |
Why?
|
| Erythrocyte Transfusion | 4 | 2022 | 72 | 1.560 |
Why?
|
| Endothelins | 15 | 2010 | 57 | 1.560 |
Why?
|
| Treatment Outcome | 32 | 2022 | 7029 | 1.540 |
Why?
|
| Upper Gastrointestinal Tract | 4 | 2015 | 9 | 1.520 |
Why?
|
| Cell Cycle Proteins | 3 | 2022 | 230 | 1.480 |
Why?
|
| Hepatorenal Syndrome | 6 | 2016 | 16 | 1.470 |
Why?
|
| Colonic Neoplasms | 7 | 2016 | 299 | 1.470 |
Why?
|
| Hepatocytes | 10 | 2017 | 205 | 1.460 |
Why?
|
| Diagnosis, Differential | 22 | 2021 | 1140 | 1.450 |
Why?
|
| Evidence-Based Medicine | 5 | 2020 | 438 | 1.420 |
Why?
|
| Collagen Type I | 8 | 2020 | 175 | 1.410 |
Why?
|
| Acute Kidney Injury | 5 | 2019 | 232 | 1.400 |
Why?
|
| Liver Failure, Acute | 4 | 2021 | 49 | 1.390 |
Why?
|
| Risk Factors | 26 | 2023 | 5731 | 1.380 |
Why?
|
| Alanine Transaminase | 12 | 2021 | 137 | 1.360 |
Why?
|
| Esophageal Diseases | 2 | 2020 | 95 | 1.290 |
Why?
|
| Severity of Illness Index | 14 | 2022 | 1851 | 1.290 |
Why?
|
| Length of Stay | 11 | 2020 | 780 | 1.280 |
Why?
|
| Nitric Oxide Synthase | 11 | 2011 | 163 | 1.250 |
Why?
|
| Bacterial Infections | 3 | 2022 | 163 | 1.250 |
Why?
|
| Peptic Ulcer Hemorrhage | 5 | 2014 | 26 | 1.240 |
Why?
|
| Serum Response Factor | 3 | 2020 | 15 | 1.240 |
Why?
|
| Phosphoproteins | 3 | 2014 | 202 | 1.230 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 40 | 1.220 |
Why?
|
| Internship and Residency | 6 | 2022 | 596 | 1.200 |
Why?
|
| Prognosis | 18 | 2021 | 2093 | 1.190 |
Why?
|
| Myofibroblasts | 3 | 2018 | 60 | 1.180 |
Why?
|
| United States | 31 | 2021 | 7367 | 1.140 |
Why?
|
| Nuclear Proteins | 2 | 2020 | 271 | 1.140 |
Why?
|
| PPAR gamma | 5 | 2011 | 95 | 1.130 |
Why?
|
| Bacteremia | 2 | 2022 | 155 | 1.130 |
Why?
|
| Hemorrhage | 4 | 2019 | 328 | 1.130 |
Why?
|
| Algorithms | 7 | 2023 | 1196 | 1.110 |
Why?
|
| Phosphorylation | 12 | 2022 | 1200 | 1.110 |
Why?
|
| Aspartate Aminotransferases | 9 | 2021 | 87 | 1.100 |
Why?
|
| Lypressin | 4 | 2013 | 5 | 1.090 |
Why?
|
| Fellowships and Scholarships | 4 | 2022 | 127 | 1.080 |
Why?
|
| Caveolin 1 | 2 | 2017 | 59 | 1.060 |
Why?
|
| Transcription Factors | 2 | 2020 | 753 | 1.050 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 286 | 1.040 |
Why?
|
| Patient Transfer | 2 | 2020 | 86 | 1.030 |
Why?
|
| Warfarin | 5 | 2019 | 93 | 1.030 |
Why?
|
| Endoscopy, Digestive System | 7 | 2019 | 78 | 1.030 |
Why?
|
| Conscious Sedation | 2 | 2019 | 61 | 1.030 |
Why?
|
| Aged, 80 and over | 25 | 2020 | 4848 | 1.030 |
Why?
|
| Hydrothorax | 2 | 2016 | 7 | 1.030 |
Why?
|
| Physicians, Primary Care | 2 | 2019 | 46 | 1.020 |
Why?
|
| Phenylbutyrates | 3 | 2015 | 7 | 1.010 |
Why?
|
| Gene Expression Regulation | 10 | 2020 | 1293 | 1.010 |
Why?
|
| Glycerol | 3 | 2015 | 26 | 0.990 |
Why?
|
| Rifamycins | 3 | 2022 | 4 | 0.990 |
Why?
|
| RNA, Messenger | 27 | 2022 | 1664 | 0.990 |
Why?
|
| Causality | 4 | 2022 | 82 | 0.960 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2020 | 175 | 0.960 |
Why?
|
| Peritonitis | 2 | 2022 | 46 | 0.950 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 249 | 0.950 |
Why?
|
| Blood Transfusion | 4 | 2020 | 205 | 0.950 |
Why?
|
| Sclerotherapy | 6 | 2019 | 10 | 0.940 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 159 | 0.940 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2021 | 14 | 0.900 |
Why?
|
| Portal Pressure | 7 | 2021 | 9 | 0.890 |
Why?
|
| Prospective Studies | 24 | 2022 | 3705 | 0.890 |
Why?
|
| Cytoskeleton | 3 | 2019 | 84 | 0.880 |
Why?
|
| Physicians | 5 | 2022 | 324 | 0.870 |
Why?
|
| Young Adult | 18 | 2020 | 5717 | 0.860 |
Why?
|
| Mice | 24 | 2022 | 8474 | 0.850 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2022 | 6 | 0.850 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 772 | 0.840 |
Why?
|
| Focal Adhesions | 1 | 2022 | 25 | 0.840 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2019 | 9 | 0.830 |
Why?
|
| Microfilament Proteins | 2 | 2020 | 102 | 0.830 |
Why?
|
| Fibrosis | 5 | 2022 | 371 | 0.830 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 306 | 0.820 |
Why?
|
| Choledocholithiasis | 2 | 2014 | 14 | 0.820 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 3259 | 0.810 |
Why?
|
| Electronic Health Records | 5 | 2020 | 374 | 0.800 |
Why?
|
| Predictive Value of Tests | 12 | 2021 | 1465 | 0.800 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2020 | 9 | 0.800 |
Why?
|
| Clinical Competence | 4 | 2015 | 657 | 0.790 |
Why?
|
| Escherichia coli Infections | 2 | 2018 | 47 | 0.790 |
Why?
|
| Biomarkers | 13 | 2022 | 1593 | 0.780 |
Why?
|
| Hepatitis | 3 | 2017 | 25 | 0.780 |
Why?
|
| Disease Management | 2 | 2020 | 248 | 0.780 |
Why?
|
| Digestive System Diseases | 1 | 2021 | 16 | 0.780 |
Why?
|
| Patient Admission | 2 | 2016 | 99 | 0.780 |
Why?
|
| Gastroenterologists | 1 | 2021 | 11 | 0.770 |
Why?
|
| Academies and Institutes | 1 | 2021 | 31 | 0.770 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 71 | 0.770 |
Why?
|
| Staff Development | 1 | 2021 | 35 | 0.770 |
Why?
|
| Career Mobility | 1 | 2021 | 34 | 0.760 |
Why?
|
| Granuloma | 1 | 2021 | 21 | 0.760 |
Why?
|
| Aspirin | 6 | 2017 | 295 | 0.750 |
Why?
|
| Research | 5 | 2020 | 214 | 0.750 |
Why?
|
| Blood Cell Count | 1 | 2020 | 35 | 0.750 |
Why?
|
| Pneumonia | 1 | 2022 | 110 | 0.740 |
Why?
|
| Mice, Inbred BALB C | 8 | 2020 | 532 | 0.740 |
Why?
|
| Drug-Eluting Stents | 1 | 2021 | 51 | 0.730 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2021 | 373 | 0.720 |
Why?
|
| beta-Arrestin 2 | 1 | 2020 | 29 | 0.720 |
Why?
|
| Up-Regulation | 5 | 2020 | 682 | 0.720 |
Why?
|
| Guideline Adherence | 3 | 2013 | 287 | 0.710 |
Why?
|
| Gastric Mucosa | 3 | 2020 | 77 | 0.710 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 508 | 0.710 |
Why?
|
| Ligation | 9 | 2019 | 83 | 0.710 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 2077 | 0.700 |
Why?
|
| Anesthesia | 1 | 2021 | 120 | 0.700 |
Why?
|
| Arrestins | 1 | 2020 | 92 | 0.700 |
Why?
|
| Airway Extubation | 1 | 2020 | 17 | 0.700 |
Why?
|
| Argon Plasma Coagulation | 1 | 2019 | 2 | 0.690 |
Why?
|
| Cell Transdifferentiation | 2 | 2022 | 12 | 0.690 |
Why?
|
| Ischemia | 2 | 2017 | 229 | 0.690 |
Why?
|
| Interpersonal Relations | 1 | 2021 | 209 | 0.680 |
Why?
|
| Fentanyl | 1 | 2019 | 26 | 0.680 |
Why?
|
| Electrocoagulation | 2 | 2015 | 35 | 0.680 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 137 | 0.680 |
Why?
|
| Midazolam | 1 | 2019 | 46 | 0.680 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 19 | 0.680 |
Why?
|
| Time Factors | 19 | 2020 | 4655 | 0.670 |
Why?
|
| Blood Culture | 1 | 2019 | 15 | 0.670 |
Why?
|
| Mifepristone | 1 | 2019 | 7 | 0.670 |
Why?
|
| Stomach | 3 | 2017 | 80 | 0.660 |
Why?
|
| Early Diagnosis | 2 | 2018 | 122 | 0.660 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 76 | 0.660 |
Why?
|
| Adenocarcinoma | 5 | 2016 | 475 | 0.660 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 212 | 0.660 |
Why?
|
| Education, Medical, Continuing | 3 | 2015 | 136 | 0.660 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 191 | 0.650 |
Why?
|
| Extracellular Matrix | 9 | 2020 | 493 | 0.650 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 190 | 0.650 |
Why?
|
| Liver Circulation | 6 | 2014 | 40 | 0.640 |
Why?
|
| Citrullinemia | 1 | 2018 | 1 | 0.640 |
Why?
|
| Lipid Droplets | 1 | 2018 | 4 | 0.640 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 2018 | 1 | 0.640 |
Why?
|
| Neostigmine | 1 | 2018 | 2 | 0.640 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 167 | 0.640 |
Why?
|
| Research Design | 3 | 2022 | 729 | 0.640 |
Why?
|
| Pyrrolidines | 2 | 2009 | 45 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2018 | 331 | 0.630 |
Why?
|
| Conservative Treatment | 1 | 2018 | 8 | 0.630 |
Why?
|
| Critical Illness | 1 | 2020 | 191 | 0.620 |
Why?
|
| Retinoids | 2 | 2018 | 122 | 0.620 |
Why?
|
| Peptic Ulcer | 2 | 2017 | 37 | 0.620 |
Why?
|
| Portal System | 2 | 2014 | 5 | 0.620 |
Why?
|
| Mass Screening | 7 | 2013 | 843 | 0.620 |
Why?
|
| Education, Medical, Graduate | 3 | 2018 | 214 | 0.610 |
Why?
|
| Research Personnel | 4 | 2022 | 83 | 0.610 |
Why?
|
| Bile Ducts | 9 | 2020 | 59 | 0.610 |
Why?
|
| Models, Theoretical | 2 | 2018 | 384 | 0.610 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 125 | 0.610 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 240 | 0.600 |
Why?
|
| Colon | 5 | 2017 | 168 | 0.600 |
Why?
|
| Texas | 5 | 2016 | 92 | 0.600 |
Why?
|
| Transforming Growth Factor beta | 5 | 2022 | 384 | 0.600 |
Why?
|
| Carbon Tetrachloride | 9 | 2013 | 15 | 0.590 |
Why?
|
| Comorbidity | 7 | 2019 | 1426 | 0.590 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 166 | 0.590 |
Why?
|
| Cholestasis | 2 | 2016 | 90 | 0.590 |
Why?
|
| Mice, Knockout | 8 | 2022 | 1692 | 0.580 |
Why?
|
| Aspartic Acid Endopeptidases | 4 | 2008 | 47 | 0.580 |
Why?
|
| Metalloendopeptidases | 4 | 2008 | 67 | 0.580 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 12 | 0.580 |
Why?
|
| Dietary Supplements | 3 | 2021 | 332 | 0.580 |
Why?
|
| Tyrosine | 3 | 2014 | 196 | 0.580 |
Why?
|
| Disease Models, Animal | 11 | 2022 | 2550 | 0.580 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 170 | 0.580 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 106 | 0.580 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 1 | 2017 | 3 | 0.580 |
Why?
|
| Medical Waste Disposal | 1 | 2017 | 3 | 0.580 |
Why?
|
| Chronic Disease | 9 | 2021 | 1330 | 0.580 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2016 | 6 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2021 | 2324 | 0.570 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 23 | 0.560 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 63 | 0.560 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 19 | 0.560 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2017 | 48 | 0.560 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 253 | 0.560 |
Why?
|
| Chelating Agents | 2 | 2016 | 47 | 0.550 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2016 | 2 | 0.550 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 156 | 0.550 |
Why?
|
| Curriculum | 3 | 2020 | 575 | 0.550 |
Why?
|
| Peritoneum | 1 | 2016 | 27 | 0.540 |
Why?
|
| Lymphoma | 1 | 2016 | 116 | 0.540 |
Why?
|
| Cholangiography | 2 | 2014 | 55 | 0.540 |
Why?
|
| Liver, Artificial | 1 | 2016 | 2 | 0.540 |
Why?
|
| Clinical Trials as Topic | 8 | 2021 | 848 | 0.540 |
Why?
|
| Sensitivity and Specificity | 14 | 2013 | 1753 | 0.540 |
Why?
|
| Case-Control Studies | 6 | 2020 | 1553 | 0.530 |
Why?
|
| Technetium | 1 | 2016 | 38 | 0.530 |
Why?
|
| Bilirubin | 4 | 2021 | 51 | 0.530 |
Why?
|
| Intestinal Diseases | 2 | 2005 | 25 | 0.530 |
Why?
|
| Hemodynamics | 2 | 2016 | 705 | 0.530 |
Why?
|
| Health Resources | 1 | 2016 | 76 | 0.530 |
Why?
|
| Jaundice | 2 | 2016 | 13 | 0.530 |
Why?
|
| Vasodilation | 3 | 2017 | 85 | 0.520 |
Why?
|
| Pasteurella Infections | 1 | 2015 | 5 | 0.520 |
Why?
|
| Pasteurella multocida | 1 | 2015 | 6 | 0.520 |
Why?
|
| Surveys and Questionnaires | 9 | 2022 | 2800 | 0.520 |
Why?
|
| Cognition Disorders | 2 | 2016 | 342 | 0.520 |
Why?
|
| Gastrointestinal Contents | 1 | 2015 | 13 | 0.520 |
Why?
|
| Fibronectins | 5 | 2013 | 130 | 0.520 |
Why?
|
| Creatinine | 2 | 2015 | 243 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 5 | 2016 | 1026 | 0.510 |
Why?
|
| Reference Values | 7 | 2020 | 579 | 0.510 |
Why?
|
| Personnel Selection | 1 | 2015 | 37 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 468 | 0.510 |
Why?
|
| Genetic Therapy | 4 | 2001 | 291 | 0.510 |
Why?
|
| Zebrafish | 2 | 2019 | 187 | 0.510 |
Why?
|
| Bites and Stings | 1 | 2015 | 34 | 0.500 |
Why?
|
| Angiodysplasia | 1 | 2015 | 4 | 0.500 |
Why?
|
| Cecal Diseases | 1 | 2015 | 6 | 0.500 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 1046 | 0.500 |
Why?
|
| Oxides | 1 | 2015 | 47 | 0.500 |
Why?
|
| Octreotide | 2 | 2015 | 21 | 0.490 |
Why?
|
| beta-Alanine | 1 | 2015 | 20 | 0.490 |
Why?
|
| Cross Infection | 1 | 2017 | 195 | 0.490 |
Why?
|
| Early Detection of Cancer | 4 | 2013 | 454 | 0.490 |
Why?
|
| Antithrombins | 1 | 2015 | 32 | 0.490 |
Why?
|
| Acute Disease | 9 | 2014 | 658 | 0.480 |
Why?
|
| Gastrostomy | 2 | 2013 | 110 | 0.480 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2014 | 43 | 0.480 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 115 | 0.480 |
Why?
|
| Benzimidazoles | 2 | 2015 | 128 | 0.480 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2014 | 59 | 0.480 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2019 | 14 | 0.470 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 26 | 0.470 |
Why?
|
| Collagen | 11 | 2018 | 636 | 0.470 |
Why?
|
| Hyperammonemia | 1 | 2014 | 4 | 0.470 |
Why?
|
| Plant Preparations | 1 | 2014 | 18 | 0.470 |
Why?
|
| Helicobacter pylori | 2 | 2013 | 54 | 0.470 |
Why?
|
| Carbon | 1 | 2015 | 122 | 0.470 |
Why?
|
| Sterilization | 2 | 2013 | 29 | 0.470 |
Why?
|
| Muscle, Smooth | 3 | 2010 | 117 | 0.470 |
Why?
|
| Adipocytes | 7 | 1996 | 88 | 0.470 |
Why?
|
| Immunohistochemistry | 10 | 2014 | 1174 | 0.470 |
Why?
|
| Protein Binding | 6 | 2017 | 1027 | 0.460 |
Why?
|
| Prevalence | 7 | 2020 | 1619 | 0.460 |
Why?
|
| Cytokines | 8 | 2019 | 866 | 0.460 |
Why?
|
| Genetic Testing | 1 | 2015 | 159 | 0.460 |
Why?
|
| Societies, Medical | 4 | 2020 | 403 | 0.460 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 191 | 0.460 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 3 | 2022 | 6 | 0.450 |
Why?
|
| Anesthetics, Intravenous | 1 | 2013 | 27 | 0.450 |
Why?
|
| Pleural Effusion | 1 | 2014 | 74 | 0.450 |
Why?
|
| Judgment | 1 | 2013 | 40 | 0.450 |
Why?
|
| Hepatitis B | 2 | 2020 | 42 | 0.450 |
Why?
|
| Preoperative Care | 1 | 2015 | 275 | 0.450 |
Why?
|
| Patient Safety | 2 | 2013 | 202 | 0.450 |
Why?
|
| Propofol | 1 | 2013 | 36 | 0.450 |
Why?
|
| Electronics, Medical | 1 | 2013 | 4 | 0.450 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 16 | 0.450 |
Why?
|
| Colchicine | 4 | 2008 | 48 | 0.440 |
Why?
|
| Adolescent | 12 | 2020 | 8912 | 0.440 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 49 | 0.440 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 40 | 0.440 |
Why?
|
| Polytetrafluoroethylene | 1 | 2013 | 55 | 0.430 |
Why?
|
| Reminder Systems | 1 | 2013 | 39 | 0.430 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 445 | 0.430 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 82 | 0.430 |
Why?
|
| Echocardiography | 1 | 2016 | 515 | 0.430 |
Why?
|
| Ultrasonography, Doppler | 1 | 2013 | 57 | 0.430 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 371 | 0.420 |
Why?
|
| Calcitriol | 1 | 2013 | 106 | 0.420 |
Why?
|
| Equipment Failure | 1 | 2013 | 112 | 0.420 |
Why?
|
| Gene Expression | 7 | 2014 | 770 | 0.420 |
Why?
|
| Ligands | 4 | 2022 | 317 | 0.420 |
Why?
|
| Cell Movement | 5 | 2020 | 630 | 0.410 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 711 | 0.410 |
Why?
|
| Polyps | 2 | 2012 | 12 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 411 | 0.410 |
Why?
|
| Receptors, Transforming Growth Factor beta | 3 | 2017 | 56 | 0.410 |
Why?
|
| Incidence | 8 | 2021 | 1603 | 0.410 |
Why?
|
| Adenoma | 3 | 2014 | 132 | 0.410 |
Why?
|
| Serum Albumin | 1 | 2012 | 104 | 0.410 |
Why?
|
| Hepatic Veins | 1 | 2012 | 13 | 0.410 |
Why?
|
| Demography | 4 | 2017 | 279 | 0.400 |
Why?
|
| Models, Statistical | 2 | 2015 | 448 | 0.400 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 221 | 0.400 |
Why?
|
| South Carolina | 5 | 2020 | 2752 | 0.400 |
Why?
|
| Expert Testimony | 2 | 2021 | 47 | 0.400 |
Why?
|
| Premenopause | 3 | 2020 | 57 | 0.400 |
Why?
|
| Age Factors | 5 | 2020 | 1864 | 0.400 |
Why?
|
| Water | 1 | 2013 | 230 | 0.400 |
Why?
|
| Remission Induction | 3 | 2021 | 111 | 0.390 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2017 | 348 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 629 | 0.390 |
Why?
|
| Mutation | 3 | 2016 | 1213 | 0.390 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 71 | 0.380 |
Why?
|
| Pyridines | 1 | 2013 | 261 | 0.380 |
Why?
|
| Recurrence | 8 | 2014 | 948 | 0.380 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 40 | 0.370 |
Why?
|
| Hemostatic Techniques | 2 | 2010 | 23 | 0.370 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 39 | 0.370 |
Why?
|
| Lactation | 1 | 2011 | 110 | 0.370 |
Why?
|
| Phenotype | 7 | 2022 | 947 | 0.370 |
Why?
|
| Macrophages | 2 | 2018 | 647 | 0.370 |
Why?
|
| Sulfonamides | 3 | 2009 | 141 | 0.370 |
Why?
|
| Stroke | 3 | 2022 | 2163 | 0.360 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2011 | 140 | 0.360 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2010 | 6 | 0.360 |
Why?
|
| Vasoconstriction | 3 | 2017 | 81 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 442 | 0.360 |
Why?
|
| Homeostasis | 1 | 2012 | 291 | 0.360 |
Why?
|
| Cytoskeletal Proteins | 3 | 2016 | 108 | 0.360 |
Why?
|
| Immunoblotting | 5 | 2011 | 254 | 0.350 |
Why?
|
| Sepsis | 1 | 2013 | 233 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 756 | 0.350 |
Why?
|
| Barium Sulfate | 3 | 2006 | 66 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2011 | 626 | 0.350 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 219 | 0.350 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 581 | 0.350 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 136 | 0.350 |
Why?
|
| Angiotensin II | 5 | 2008 | 220 | 0.350 |
Why?
|
| Patient Satisfaction | 4 | 2009 | 378 | 0.350 |
Why?
|
| Fetal Mortality | 1 | 2009 | 1 | 0.350 |
Why?
|
| Alkaline Phosphatase | 3 | 2018 | 71 | 0.350 |
Why?
|
| Cell Membrane | 5 | 2020 | 525 | 0.350 |
Why?
|
| Membrane Proteins | 4 | 2016 | 617 | 0.340 |
Why?
|
| Duodenal Neoplasms | 2 | 2016 | 9 | 0.340 |
Why?
|
| Disease Progression | 6 | 2020 | 1038 | 0.340 |
Why?
|
| Medication Adherence | 1 | 2013 | 335 | 0.340 |
Why?
|
| Receptors, Endothelin | 6 | 2010 | 30 | 0.340 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2011 | 237 | 0.340 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2009 | 11 | 0.340 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 378 | 0.340 |
Why?
|
| Cefazolin | 2 | 2022 | 19 | 0.340 |
Why?
|
| Cholecystitis | 1 | 2009 | 12 | 0.340 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 567 | 0.340 |
Why?
|
| Sex Factors | 3 | 2020 | 1266 | 0.340 |
Why?
|
| Endothelin B Receptor Antagonists | 1 | 2009 | 11 | 0.330 |
Why?
|
| Blood Coagulation Disorders | 2 | 2019 | 45 | 0.330 |
Why?
|
| Protein Transport | 5 | 2017 | 280 | 0.330 |
Why?
|
| Neoplasms | 3 | 2019 | 1667 | 0.330 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2009 | 22 | 0.330 |
Why?
|
| Bile Duct Diseases | 1 | 2009 | 28 | 0.330 |
Why?
|
| Enzyme Activation | 4 | 2014 | 791 | 0.330 |
Why?
|
| Patient Readmission | 2 | 2023 | 267 | 0.330 |
Why?
|
| Diverticulum | 2 | 2017 | 29 | 0.330 |
Why?
|
| Receptor, Endothelin B | 3 | 2017 | 34 | 0.330 |
Why?
|
| Professional Practice | 1 | 2009 | 47 | 0.320 |
Why?
|
| Logistic Models | 5 | 2013 | 1420 | 0.320 |
Why?
|
| src-Family Kinases | 1 | 2009 | 91 | 0.320 |
Why?
|
| Melena | 4 | 2016 | 8 | 0.320 |
Why?
|
| Liver Abscess | 2 | 2000 | 9 | 0.320 |
Why?
|
| Pancreatic Diseases | 1 | 2009 | 66 | 0.320 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 377 | 0.320 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 365 | 0.320 |
Why?
|
| Kupffer Cells | 6 | 2011 | 75 | 0.310 |
Why?
|
| Angiography | 4 | 2005 | 194 | 0.310 |
Why?
|
| Stents | 1 | 2013 | 657 | 0.310 |
Why?
|
| Mentors | 2 | 2021 | 81 | 0.310 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2008 | 69 | 0.310 |
Why?
|
| Aging | 2 | 2015 | 911 | 0.310 |
Why?
|
| Mice, 129 Strain | 3 | 2019 | 44 | 0.310 |
Why?
|
| Referral and Consultation | 2 | 2020 | 383 | 0.310 |
Why?
|
| Nitric Oxide Donors | 1 | 2008 | 54 | 0.300 |
Why?
|
| Interleukin-10 | 2 | 2006 | 144 | 0.300 |
Why?
|
| Hematemesis | 3 | 2016 | 14 | 0.300 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 172 | 0.300 |
Why?
|
| Premature Birth | 1 | 2009 | 150 | 0.300 |
Why?
|
| Mental Disorders | 1 | 2013 | 659 | 0.290 |
Why?
|
| Inflammation | 3 | 2022 | 1030 | 0.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 143 | 0.290 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 154 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2021 | 931 | 0.290 |
Why?
|
| Rectal Diseases | 1 | 2007 | 13 | 0.290 |
Why?
|
| Amino Acid Oxidoreductases | 2 | 2018 | 10 | 0.290 |
Why?
|
| Digital Rectal Examination | 1 | 2006 | 11 | 0.280 |
Why?
|
| Integrins | 3 | 2022 | 115 | 0.280 |
Why?
|
| Liver Failure | 2 | 2017 | 27 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 710 | 0.280 |
Why?
|
| Pregnancy | 4 | 2018 | 2334 | 0.280 |
Why?
|
| Peptide Fragments | 2 | 2020 | 483 | 0.280 |
Why?
|
| Gastric Bypass | 1 | 2007 | 83 | 0.280 |
Why?
|
| Secondary Prevention | 4 | 2014 | 291 | 0.280 |
Why?
|
| Complement C3 | 1 | 2007 | 101 | 0.280 |
Why?
|
| Mutation, Missense | 2 | 2019 | 112 | 0.270 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 109 | 0.270 |
Why?
|
| Apoptosis | 2 | 2018 | 1641 | 0.270 |
Why?
|
| Administration, Oral | 3 | 2017 | 411 | 0.270 |
Why?
|
| Epithelial Cells | 3 | 2015 | 431 | 0.260 |
Why?
|
| Sigmoidoscopy | 2 | 2006 | 38 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2008 | 1745 | 0.260 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2017 | 7 | 0.260 |
Why?
|
| Cell Proliferation | 4 | 2020 | 1174 | 0.260 |
Why?
|
| Duodenal Ulcer | 1 | 2005 | 16 | 0.250 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 150 | 0.250 |
Why?
|
| Stomach Ulcer | 1 | 2005 | 14 | 0.250 |
Why?
|
| Cardiovascular Agents | 1 | 2006 | 82 | 0.250 |
Why?
|
| Brain | 1 | 2016 | 2176 | 0.250 |
Why?
|
| Liver Regeneration | 2 | 2021 | 38 | 0.250 |
Why?
|
| Paracentesis | 2 | 2016 | 25 | 0.250 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 93 | 0.250 |
Why?
|
| Diverticulosis, Colonic | 1 | 2004 | 1 | 0.250 |
Why?
|
| Digestive System | 3 | 1999 | 35 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 2223 | 0.250 |
Why?
|
| Dibenzothiazepines | 1 | 2004 | 15 | 0.250 |
Why?
|
| Adenomatous Polyps | 1 | 2004 | 18 | 0.250 |
Why?
|
| Ferritins | 2 | 2019 | 49 | 0.240 |
Why?
|
| HLA-B Antigens | 2 | 2021 | 7 | 0.240 |
Why?
|
| Glycosylation | 2 | 2022 | 185 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 6 | 2019 | 2791 | 0.240 |
Why?
|
| Contrast Media | 3 | 2006 | 595 | 0.240 |
Why?
|
| Urea | 2 | 2015 | 51 | 0.240 |
Why?
|
| Tea | 2 | 2021 | 23 | 0.240 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 91 | 0.240 |
Why?
|
| Forecasting | 3 | 2019 | 277 | 0.240 |
Why?
|
| Water Microbiology | 2 | 2013 | 24 | 0.240 |
Why?
|
| Anoctamin-1 | 3 | 2020 | 3 | 0.240 |
Why?
|
| Sirolimus | 1 | 2005 | 118 | 0.240 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 149 | 0.240 |
Why?
|
| Hemangioma | 1 | 2004 | 51 | 0.240 |
Why?
|
| Machine Learning | 2 | 2023 | 170 | 0.230 |
Why?
|
| Protein Isoforms | 2 | 2017 | 246 | 0.230 |
Why?
|
| Endothelin-Converting Enzymes | 4 | 2008 | 15 | 0.230 |
Why?
|
| Endoplasmic Reticulum Stress | 2 | 2022 | 99 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2002 | 376 | 0.230 |
Why?
|
| Isoenzymes | 3 | 2005 | 308 | 0.230 |
Why?
|
| Pyridones | 2 | 2017 | 40 | 0.230 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 498 | 0.230 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2003 | 8 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2015 | 2007 | 0.230 |
Why?
|
| Disease Susceptibility | 3 | 2012 | 179 | 0.230 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 940 | 0.230 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2003 | 11 | 0.230 |
Why?
|
| Glutamine | 2 | 2014 | 45 | 0.230 |
Why?
|
| Analysis of Variance | 4 | 2013 | 1040 | 0.230 |
Why?
|
| Fatty Liver | 2 | 2019 | 97 | 0.220 |
Why?
|
| Pandemics | 3 | 2022 | 352 | 0.220 |
Why?
|
| Carbon Monoxide | 3 | 2003 | 58 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2003 | 9 | 0.220 |
Why?
|
| Hematocrit | 2 | 2014 | 70 | 0.220 |
Why?
|
| Carbon Tetrachloride Poisoning | 4 | 1997 | 5 | 0.220 |
Why?
|
| Base Sequence | 5 | 2012 | 1015 | 0.220 |
Why?
|
| Cholangiocarcinoma | 1 | 2003 | 20 | 0.220 |
Why?
|
| Isosorbide Dinitrate | 1 | 2003 | 6 | 0.220 |
Why?
|
| Colitis | 3 | 2004 | 156 | 0.220 |
Why?
|
| Transfection | 4 | 2015 | 782 | 0.220 |
Why?
|
| Survival Rate | 3 | 2018 | 1056 | 0.220 |
Why?
|
| Cyproterone | 1 | 2022 | 2 | 0.210 |
Why?
|
| Talin | 1 | 2022 | 3 | 0.210 |
Why?
|
| Vinculin | 1 | 2022 | 15 | 0.210 |
Why?
|
| Propranolol | 1 | 2003 | 103 | 0.210 |
Why?
|
| Adipose Tissue | 3 | 1992 | 221 | 0.210 |
Why?
|
| Rodentia | 1 | 2022 | 27 | 0.210 |
Why?
|
| Computers | 1 | 2022 | 63 | 0.210 |
Why?
|
| Tablets | 1 | 2022 | 19 | 0.210 |
Why?
|
| Lipopolysaccharides | 4 | 2011 | 455 | 0.210 |
Why?
|
| ROC Curve | 4 | 2021 | 392 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 792 | 0.210 |
Why?
|
| Cyanoacrylates | 1 | 2022 | 8 | 0.210 |
Why?
|
| Diet, Western | 1 | 2022 | 17 | 0.200 |
Why?
|
| Dyphylline | 1 | 2022 | 1 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2004 | 247 | 0.200 |
Why?
|
| Capsule Endoscopy | 2 | 2015 | 10 | 0.200 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 138 | 0.200 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 649 | 0.200 |
Why?
|
| Somatostatinoma | 1 | 2001 | 3 | 0.200 |
Why?
|
| Body Weight | 3 | 2011 | 554 | 0.200 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2022 | 16 | 0.200 |
Why?
|
| Primary Prevention | 2 | 2014 | 115 | 0.200 |
Why?
|
| Dietary Carbohydrates | 1 | 2022 | 27 | 0.200 |
Why?
|
| Garcinia cambogia | 1 | 2021 | 1 | 0.200 |
Why?
|
| Registries | 2 | 2016 | 733 | 0.200 |
Why?
|
| Genotype | 3 | 2014 | 786 | 0.200 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 70 | 0.200 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 81 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 2279 | 0.200 |
Why?
|
| Enbucrilate | 1 | 2001 | 5 | 0.190 |
Why?
|
| Vaccines, Inactivated | 1 | 2021 | 3 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 148 | 0.190 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 8 | 0.190 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 49 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 615 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 514 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2023 | 206 | 0.190 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1738 | 0.190 |
Why?
|
| HEK293 Cells | 2 | 2019 | 326 | 0.190 |
Why?
|
| RNA-Binding Proteins | 1 | 2003 | 215 | 0.190 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.190 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 284 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 307 | 0.190 |
Why?
|
| beta-Arrestin 1 | 1 | 2020 | 22 | 0.190 |
Why?
|
| Bayes Theorem | 1 | 2023 | 307 | 0.190 |
Why?
|
| Jejunal Neoplasms | 2 | 2016 | 2 | 0.190 |
Why?
|
| Endosonography | 1 | 2022 | 177 | 0.190 |
Why?
|
| Proteome | 1 | 2021 | 87 | 0.190 |
Why?
|
| beta-Arrestins | 1 | 2020 | 80 | 0.180 |
Why?
|
| Models, Biological | 5 | 2017 | 981 | 0.180 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 69 | 0.180 |
Why?
|
| Propensity Score | 1 | 2020 | 117 | 0.180 |
Why?
|
| Vascular Resistance | 3 | 2014 | 179 | 0.180 |
Why?
|
| Hydroxyproline | 2 | 2013 | 33 | 0.180 |
Why?
|
| Biliary Tract | 2 | 2010 | 17 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 110 | 0.180 |
Why?
|
| Protein Precursors | 3 | 2011 | 105 | 0.180 |
Why?
|
| Receptors, Interleukin-13 | 1 | 2020 | 1 | 0.180 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2020 | 9 | 0.180 |
Why?
|
| Cell Polarity | 1 | 2020 | 49 | 0.180 |
Why?
|
| Down-Regulation | 2 | 2012 | 447 | 0.180 |
Why?
|
| Kidney Diseases | 2 | 2015 | 307 | 0.180 |
Why?
|
| Smad Proteins, Receptor-Regulated | 1 | 2020 | 3 | 0.180 |
Why?
|
| Postmenopause | 1 | 2020 | 93 | 0.180 |
Why?
|
| Pain Measurement | 1 | 2001 | 328 | 0.180 |
Why?
|
| Metals | 1 | 2021 | 100 | 0.180 |
Why?
|
| Nipecotic Acids | 1 | 2020 | 11 | 0.180 |
Why?
|
| Cysts | 1 | 2000 | 70 | 0.180 |
Why?
|
| Chlorides | 2 | 2020 | 68 | 0.180 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2019 | 8 | 0.170 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1999 | 14 | 0.170 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 235 | 0.170 |
Why?
|
| Consensus | 1 | 2020 | 211 | 0.170 |
Why?
|
| Fibroblasts | 2 | 2022 | 902 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 59 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2020 | 622 | 0.170 |
Why?
|
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2019 | 21 | 0.170 |
Why?
|
| Vaccination | 1 | 2021 | 189 | 0.170 |
Why?
|
| Trace Elements | 1 | 2019 | 23 | 0.170 |
Why?
|
| RNA Interference | 3 | 2015 | 266 | 0.170 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2019 | 1 | 0.170 |
Why?
|
| Prosthesis Design | 1 | 2021 | 301 | 0.170 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 546 | 0.170 |
Why?
|
| Prothrombin Time | 1 | 2019 | 24 | 0.170 |
Why?
|
| Cell Nucleus | 1 | 2020 | 305 | 0.170 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2019 | 9 | 0.170 |
Why?
|
| International Normalized Ratio | 1 | 2019 | 23 | 0.170 |
Why?
|
| Anti-Ulcer Agents | 1 | 1999 | 47 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 481 | 0.170 |
Why?
|
| Partial Thromboplastin Time | 1 | 2019 | 57 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2000 | 139 | 0.170 |
Why?
|
| Cushing Syndrome | 1 | 2019 | 7 | 0.170 |
Why?
|
| Portal Vein | 1 | 2019 | 46 | 0.170 |
Why?
|
| Blood Coagulation Factors | 1 | 2019 | 44 | 0.170 |
Why?
|
| Omeprazole | 1 | 1999 | 53 | 0.170 |
Why?
|
| Cell Adhesion | 1 | 2020 | 324 | 0.170 |
Why?
|
| Liver Abscess, Amebic | 1 | 1999 | 2 | 0.170 |
Why?
|
| CA-125 Antigen | 1 | 1999 | 5 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 103 | 0.170 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 123 | 0.170 |
Why?
|
| Syndrome | 2 | 2014 | 255 | 0.170 |
Why?
|
| Hepatocyte Growth Factor | 1 | 1999 | 63 | 0.170 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2019 | 41 | 0.170 |
Why?
|
| Mitragyna | 1 | 2019 | 7 | 0.160 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2019 | 31 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 69 | 0.160 |
Why?
|
| Hemorrhoids | 2 | 2017 | 5 | 0.160 |
Why?
|
| Phlebography | 1 | 1998 | 31 | 0.160 |
Why?
|
| Necrosis | 1 | 2019 | 239 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Research Support as Topic | 4 | 2018 | 58 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 223 | 0.160 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 281 | 0.160 |
Why?
|
| Amyloidosis | 1 | 1999 | 48 | 0.160 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 951 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2017 | 199 | 0.160 |
Why?
|
| Pyrazoles | 2 | 2017 | 190 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 434 | 0.160 |
Why?
|
| Career Choice | 1 | 1999 | 98 | 0.160 |
Why?
|
| Chloride Channels | 2 | 2015 | 22 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2004 | 1615 | 0.150 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2018 | 58 | 0.150 |
Why?
|
| Hyaluronic Acid | 2 | 2008 | 206 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 689 | 0.150 |
Why?
|
| Decompression, Surgical | 1 | 2018 | 55 | 0.150 |
Why?
|
| Anxiety | 1 | 2001 | 422 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 290 | 0.150 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 659 | 0.150 |
Why?
|
| Risk | 2 | 2017 | 563 | 0.150 |
Why?
|
| Cell Division | 3 | 1996 | 541 | 0.150 |
Why?
|
| Spleen | 2 | 2007 | 301 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 91 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 123 | 0.150 |
Why?
|
| Dabigatran | 1 | 2017 | 35 | 0.150 |
Why?
|
| Thrombosis | 1 | 2019 | 218 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2019 | 122 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2017 | 26 | 0.150 |
Why?
|
| Arteriovenous Malformations | 1 | 2017 | 34 | 0.150 |
Why?
|
| Th2 Cells | 1 | 1997 | 48 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2018 | 132 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2020 | 344 | 0.150 |
Why?
|
| Obesity | 3 | 2015 | 1076 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.150 |
Why?
|
| Needs Assessment | 2 | 2017 | 186 | 0.150 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 334 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 201 | 0.150 |
Why?
|
| Age Distribution | 2 | 2014 | 320 | 0.150 |
Why?
|
| Gastric Lavage | 1 | 2017 | 2 | 0.140 |
Why?
|
| Ileal Neoplasms | 1 | 2016 | 5 | 0.140 |
Why?
|
| Rectum | 1 | 2017 | 62 | 0.140 |
Why?
|
| Phosphotyrosine | 1 | 2017 | 41 | 0.140 |
Why?
|
| Th1 Cells | 1 | 1997 | 101 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 1999 | 267 | 0.140 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.140 |
Why?
|
| Isoproterenol | 1 | 2017 | 163 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
| Refuse Disposal | 1 | 2017 | 22 | 0.140 |
Why?
|
| Endoscopes | 1 | 2017 | 36 | 0.140 |
Why?
|
| Protein Domains | 1 | 2017 | 74 | 0.140 |
Why?
|
| Palliative Care | 1 | 2019 | 271 | 0.140 |
Why?
|
| Endothelium | 6 | 1999 | 98 | 0.140 |
Why?
|
| Enzyme Induction | 4 | 1998 | 119 | 0.140 |
Why?
|
| Equipment Contamination | 1 | 2017 | 38 | 0.140 |
Why?
|
| Catheterization | 3 | 2003 | 209 | 0.140 |
Why?
|
| Cause of Death | 2 | 2017 | 241 | 0.140 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2016 | 9 | 0.140 |
Why?
|
| Europe | 2 | 2018 | 196 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 64 | 0.140 |
Why?
|
| DNA, Viral | 1 | 2016 | 114 | 0.140 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2016 | 9 | 0.140 |
Why?
|
| Jaundice, Obstructive | 1 | 2016 | 8 | 0.140 |
Why?
|
| Hospitals, Public | 1 | 2016 | 22 | 0.140 |
Why?
|
| Cell Differentiation | 3 | 2017 | 1034 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 95 | 0.140 |
Why?
|
| Hemostasis | 1 | 2016 | 32 | 0.130 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2016 | 24 | 0.130 |
Why?
|
| Global Health | 1 | 2016 | 136 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 65 | 0.130 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 166 | 0.130 |
Why?
|
| Pyrroles | 1 | 2016 | 83 | 0.130 |
Why?
|
| Enema | 2 | 2006 | 23 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 150 | 0.130 |
Why?
|
| Protein Kinase C-alpha | 1 | 2015 | 24 | 0.130 |
Why?
|
| Immunocompetence | 1 | 2015 | 19 | 0.130 |
Why?
|
| Indoles | 1 | 2016 | 146 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2015 | 880 | 0.130 |
Why?
|
| Ornithine | 1 | 2015 | 9 | 0.130 |
Why?
|
| Ethylnitrosourea | 1 | 2015 | 9 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1033 | 0.130 |
Why?
|
| Arterial Pressure | 1 | 2015 | 47 | 0.130 |
Why?
|
| Capillaries | 1 | 2016 | 105 | 0.130 |
Why?
|
| Esophagus | 1 | 2017 | 303 | 0.130 |
Why?
|
| Patient Compliance | 2 | 2018 | 402 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2014 | 737 | 0.130 |
Why?
|
| Cats | 1 | 2015 | 292 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2013 | 239 | 0.120 |
Why?
|
| Cecum | 1 | 2015 | 39 | 0.120 |
Why?
|
| Blood Urea Nitrogen | 1 | 2015 | 65 | 0.120 |
Why?
|
| Cathartics | 2 | 2012 | 7 | 0.120 |
Why?
|
| Molecular Sequence Data | 4 | 2012 | 1447 | 0.120 |
Why?
|
| Dizziness | 1 | 2015 | 27 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2015 | 104 | 0.120 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1997 | 317 | 0.120 |
Why?
|
| Child | 3 | 2022 | 6405 | 0.120 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Intestinal Polyps | 1 | 2014 | 15 | 0.120 |
Why?
|
| Dogs | 1 | 2015 | 490 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2016 | 215 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2014 | 19 | 0.120 |
Why?
|
| DNA | 3 | 2006 | 597 | 0.120 |
Why?
|
| Probiotics | 1 | 2014 | 14 | 0.120 |
Why?
|
| Hepatomegaly | 2 | 2011 | 4 | 0.120 |
Why?
|
| Radiography | 2 | 2009 | 572 | 0.120 |
Why?
|
| Program Development | 1 | 2015 | 240 | 0.120 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 77 | 0.120 |
Why?
|
| Anemia, Hypochromic | 1 | 1993 | 3 | 0.120 |
Why?
|
| Professional Practice Location | 1 | 2013 | 19 | 0.120 |
Why?
|
| Ceramides | 1 | 2018 | 578 | 0.120 |
Why?
|
| RNA, Viral | 2 | 2006 | 93 | 0.120 |
Why?
|
| Reoperation | 2 | 2013 | 467 | 0.120 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2013 | 1 | 0.120 |
Why?
|
| Insurance Coverage | 2 | 2012 | 99 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2014 | 238 | 0.110 |
Why?
|
| Phenylacetates | 1 | 2013 | 18 | 0.110 |
Why?
|
| Diuretics | 1 | 2014 | 97 | 0.110 |
Why?
|
| Hospitals, Community | 1 | 2013 | 64 | 0.110 |
Why?
|
| Primary Cell Culture | 1 | 2013 | 56 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 172 | 0.110 |
Why?
|
| Internationality | 1 | 2013 | 74 | 0.110 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2013 | 10 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2014 | 124 | 0.110 |
Why?
|
| Hospitals, University | 1 | 2013 | 169 | 0.110 |
Why?
|
| Metagenome | 1 | 2013 | 17 | 0.110 |
Why?
|
| Medically Underserved Area | 1 | 2013 | 85 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2016 | 326 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2014 | 141 | 0.110 |
Why?
|
| Cryoglobulinemia | 1 | 2013 | 5 | 0.110 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 176 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 150 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2011 | 1342 | 0.110 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2013 | 6 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 147 | 0.110 |
Why?
|
| Morbidity | 2 | 2014 | 130 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 183 | 0.110 |
Why?
|
| Contraindications | 2 | 2011 | 52 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 282 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 85 | 0.110 |
Why?
|
| DNA Primers | 2 | 2011 | 302 | 0.110 |
Why?
|
| North Carolina | 2 | 2006 | 224 | 0.110 |
Why?
|
| Adenoviridae | 2 | 2006 | 295 | 0.110 |
Why?
|
| Colon, Ascending | 1 | 2012 | 3 | 0.110 |
Why?
|
| Colon, Descending | 1 | 2012 | 3 | 0.110 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 375 | 0.110 |
Why?
|
| Cell Separation | 4 | 2006 | 132 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2006 | 144 | 0.100 |
Why?
|
| Cost Savings | 1 | 2013 | 110 | 0.100 |
Why?
|
| HLA-DRB1 Chains | 1 | 2012 | 21 | 0.100 |
Why?
|
| Hospital Communication Systems | 1 | 2012 | 3 | 0.100 |
Why?
|
| Desmin | 1 | 1992 | 13 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2013 | 152 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2022 | 306 | 0.100 |
Why?
|
| Viper Venoms | 3 | 1996 | 8 | 0.100 |
Why?
|
| Mobile Applications | 1 | 2014 | 138 | 0.100 |
Why?
|
| Protective Agents | 1 | 2012 | 36 | 0.100 |
Why?
|
| Maternal Behavior | 1 | 2011 | 29 | 0.100 |
Why?
|
| Oxytocics | 1 | 2011 | 14 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 57 | 0.100 |
Why?
|
| Probability | 2 | 2009 | 245 | 0.100 |
Why?
|
| Risk Management | 2 | 2011 | 37 | 0.100 |
Why?
|
| Selection Bias | 1 | 2011 | 23 | 0.100 |
Why?
|
| Quality Control | 2 | 2011 | 81 | 0.100 |
Why?
|
| Thioacetamide | 1 | 2011 | 2 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 786 | 0.100 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2011 | 26 | 0.100 |
Why?
|
| Canada | 2 | 2009 | 267 | 0.100 |
Why?
|
| Adiponectin | 1 | 2011 | 52 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 209 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 954 | 0.090 |
Why?
|
| Oxidative Stress | 3 | 2019 | 718 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 240 | 0.090 |
Why?
|
| Pancreatic Fistula | 1 | 1990 | 23 | 0.090 |
Why?
|
| Transaminases | 2 | 2021 | 21 | 0.090 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 42 | 0.090 |
Why?
|
| Fistula | 1 | 1990 | 29 | 0.090 |
Why?
|
| Nucleotides | 1 | 2010 | 29 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 1999 | 201 | 0.090 |
Why?
|
| Animals, Newborn | 1 | 2011 | 396 | 0.090 |
Why?
|
| Pleural Diseases | 1 | 1990 | 20 | 0.090 |
Why?
|
| Kidney | 1 | 2015 | 945 | 0.090 |
Why?
|
| Kidney Transplantation | 2 | 2015 | 839 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 1 | 2010 | 35 | 0.090 |
Why?
|
| Sustained Virologic Response | 2 | 2020 | 11 | 0.090 |
Why?
|
| Extracellular Space | 1 | 2010 | 121 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 58 | 0.090 |
Why?
|
| Data Collection | 3 | 2021 | 420 | 0.090 |
Why?
|
| China | 2 | 2021 | 138 | 0.090 |
Why?
|
| Endoribonucleases | 1 | 2010 | 22 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1070 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2011 | 235 | 0.090 |
Why?
|
| Autocrine Communication | 2 | 2002 | 37 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2011 | 340 | 0.090 |
Why?
|
| Oxazoles | 1 | 2010 | 17 | 0.090 |
Why?
|
| Adenosine Triphosphate | 3 | 2020 | 314 | 0.090 |
Why?
|
| Central Nervous System Diseases | 1 | 2010 | 40 | 0.090 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2009 | 4 | 0.090 |
Why?
|
| Oxytocin | 1 | 2011 | 124 | 0.090 |
Why?
|
| Genetic Vectors | 2 | 2001 | 312 | 0.090 |
Why?
|
| Aortic Aneurysm | 1 | 1990 | 77 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2011 | 504 | 0.080 |
Why?
|
| North America | 2 | 2020 | 112 | 0.080 |
Why?
|
| Cell Line | 3 | 2020 | 1752 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2009 | 40 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2009 | 42 | 0.080 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 146 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2012 | 296 | 0.080 |
Why?
|
| Receptor, Endothelin A | 1 | 2009 | 35 | 0.080 |
Why?
|
| Asia | 1 | 2009 | 59 | 0.080 |
Why?
|
| Nitrites | 2 | 2000 | 53 | 0.080 |
Why?
|
| Pancreas | 1 | 2010 | 225 | 0.080 |
Why?
|
| Smad3 Protein | 1 | 2008 | 33 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 60 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2010 | 175 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 132 | 0.080 |
Why?
|
| Choice Behavior | 1 | 2009 | 85 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2008 | 127 | 0.080 |
Why?
|
| Random Allocation | 1 | 2009 | 442 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2008 | 89 | 0.080 |
Why?
|
| Erythrocyte Indices | 1 | 2007 | 9 | 0.080 |
Why?
|
| Pancreatitis, Chronic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Diagnostic Equipment | 1 | 2007 | 1 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2008 | 248 | 0.080 |
Why?
|
| Elasticity | 1 | 2008 | 103 | 0.080 |
Why?
|
| Fraud | 1 | 2007 | 8 | 0.070 |
Why?
|
| Anemia | 1 | 2008 | 104 | 0.070 |
Why?
|
| Tumor Escape | 2 | 2018 | 37 | 0.070 |
Why?
|
| Ketone Bodies | 1 | 2007 | 5 | 0.070 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2007 | 3 | 0.070 |
Why?
|
| Transferrin | 1 | 2007 | 94 | 0.070 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2006 | 4 | 0.070 |
Why?
|
| Patient Selection | 1 | 2011 | 592 | 0.070 |
Why?
|
| Silymarin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 38 | 0.070 |
Why?
|
| Antigens, CD | 2 | 2005 | 230 | 0.070 |
Why?
|
| Connective Tissue Cells | 1 | 2006 | 1 | 0.070 |
Why?
|
| Collagenases | 1 | 2006 | 34 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2006 | 37 | 0.070 |
Why?
|
| Antimetabolites | 1 | 2006 | 17 | 0.070 |
Why?
|
| Adoptive Transfer | 2 | 2017 | 100 | 0.070 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 75 | 0.070 |
Why?
|
| Somatostatin | 1 | 2006 | 36 | 0.070 |
Why?
|
| Tetraspanin 28 | 1 | 2005 | 4 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2006 | 191 | 0.070 |
Why?
|
| Vasopressins | 1 | 2006 | 33 | 0.070 |
Why?
|
| Professional Competence | 1 | 2006 | 100 | 0.070 |
Why?
|
| Electrophysiological Phenomena | 2 | 2020 | 20 | 0.070 |
Why?
|
| Nitrates | 1 | 2006 | 61 | 0.070 |
Why?
|
| Equipment Design | 1 | 2007 | 500 | 0.070 |
Why?
|
| Capsules | 1 | 2005 | 18 | 0.070 |
Why?
|
| Esophagoscopy | 1 | 2006 | 72 | 0.070 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2005 | 1 | 0.070 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2005 | 7 | 0.070 |
Why?
|
| Vitamin A | 2 | 2000 | 111 | 0.070 |
Why?
|
| Hemostatics | 1 | 2006 | 47 | 0.070 |
Why?
|
| Proton Pumps | 1 | 2005 | 13 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 369 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2006 | 126 | 0.060 |
Why?
|
| Health Policy | 1 | 2007 | 221 | 0.060 |
Why?
|
| Patch-Clamp Techniques | 2 | 2020 | 204 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 246 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 765 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 145 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2018 | 266 | 0.060 |
Why?
|
| Cell Line, Transformed | 3 | 2018 | 100 | 0.060 |
Why?
|
| Physical Examination | 1 | 2005 | 152 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 507 | 0.060 |
Why?
|
| Quetiapine Fumarate | 1 | 2004 | 20 | 0.060 |
Why?
|
| Dilatation, Pathologic | 1 | 2004 | 58 | 0.060 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2004 | 13 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 536 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2005 | 107 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2004 | 46 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 1851 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2004 | 164 | 0.060 |
Why?
|
| Protein Biosynthesis | 2 | 2017 | 181 | 0.060 |
Why?
|
| Culture Media, Serum-Free | 1 | 2003 | 35 | 0.060 |
Why?
|
| Common Bile Duct | 2 | 1995 | 22 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 40 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 306 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 56 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2003 | 39 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2003 | 65 | 0.050 |
Why?
|
| Catecholamines | 1 | 2003 | 73 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 322 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 694 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2000 | 1451 | 0.050 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 22 | 0.050 |
Why?
|
| Solubility | 1 | 2002 | 134 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2004 | 307 | 0.050 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 532 | 0.050 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2001 | 3 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 498 | 0.050 |
Why?
|
| Ampulla of Vater | 1 | 2001 | 34 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2001 | 17 | 0.050 |
Why?
|
| Leptin | 1 | 2002 | 80 | 0.050 |
Why?
|
| Cholelithiasis | 1 | 2001 | 66 | 0.050 |
Why?
|
| Binding Sites | 1 | 2003 | 631 | 0.050 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 39 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2003 | 294 | 0.050 |
Why?
|
| Injections | 1 | 2001 | 119 | 0.050 |
Why?
|
| Hepatitis, Chronic | 1 | 2020 | 3 | 0.050 |
Why?
|
| Tolazoline | 1 | 2000 | 2 | 0.050 |
Why?
|
| Social Class | 2 | 2013 | 127 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 248 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2000 | 26 | 0.050 |
Why?
|
| Specialization | 1 | 2020 | 66 | 0.050 |
Why?
|
| Shock | 1 | 2000 | 28 | 0.050 |
Why?
|
| Italy | 1 | 2020 | 36 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2022 | 238 | 0.050 |
Why?
|
| Cardiac Output, Low | 1 | 2000 | 52 | 0.040 |
Why?
|
| Janus Kinase 3 | 1 | 2020 | 2 | 0.040 |
Why?
|
| STAT6 Transcription Factor | 1 | 2020 | 11 | 0.040 |
Why?
|
| Venous Insufficiency | 1 | 2000 | 27 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 19 | 0.040 |
Why?
|
| Cell Size | 1 | 2000 | 76 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2000 | 219 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 78 | 0.040 |
Why?
|
| Interferons | 1 | 2000 | 36 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2000 | 35 | 0.040 |
Why?
|
| Heart-Lung Transplantation | 1 | 1999 | 2 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2022 | 176 | 0.040 |
Why?
|
| Pyloric Antrum | 1 | 1999 | 10 | 0.040 |
Why?
|
| Hypotension | 1 | 2000 | 74 | 0.040 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 64 | 0.040 |
Why?
|
| Cimetidine | 1 | 1999 | 25 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2000 | 251 | 0.040 |
Why?
|
| Lymphocyte Antigen 96 | 2 | 2011 | 10 | 0.040 |
Why?
|
| Heparin | 1 | 2000 | 205 | 0.040 |
Why?
|
| Benzodioxoles | 1 | 2019 | 30 | 0.040 |
Why?
|
| Ferrous Compounds | 1 | 1999 | 18 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 504 | 0.040 |
Why?
|
| Ovarian Cysts | 1 | 1999 | 9 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 1999 | 10 | 0.040 |
Why?
|
| Training Support | 1 | 1999 | 17 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2000 | 117 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 26 | 0.040 |
Why?
|
| Autoradiography | 2 | 1996 | 94 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 35 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2000 | 219 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 55 | 0.040 |
Why?
|
| Travel | 1 | 1999 | 38 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 2019 | 43 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2022 | 442 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 114 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2000 | 186 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 1999 | 166 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 2000 | 157 | 0.040 |
Why?
|
| Chylomicrons | 1 | 1998 | 6 | 0.040 |
Why?
|
| Benzamides | 1 | 2019 | 156 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 87 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2018 | 12 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1998 | 95 | 0.040 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 100 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2018 | 15 | 0.040 |
Why?
|
| Tosylphenylalanyl Chloromethyl Ketone | 1 | 1998 | 2 | 0.040 |
Why?
|
| Thiocarbamates | 1 | 1998 | 20 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.040 |
Why?
|
| Endotoxins | 1 | 1998 | 76 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 1998 | 31 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Proline | 1 | 1998 | 52 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2000 | 276 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2000 | 652 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 132 | 0.040 |
Why?
|
| Integrin beta1 | 1 | 1997 | 48 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 168 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1998 | 48 | 0.040 |
Why?
|
| Muscles | 1 | 1997 | 158 | 0.040 |
Why?
|
| Liposomes | 1 | 2018 | 107 | 0.040 |
Why?
|
| Microcirculation | 1 | 1997 | 77 | 0.040 |
Why?
|
| Mentoring | 1 | 2018 | 53 | 0.040 |
Why?
|
| Species Specificity | 1 | 1997 | 303 | 0.040 |
Why?
|
| Mice, SCID | 1 | 1997 | 238 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2011 | 3187 | 0.040 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 1996 | 11 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 160 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 186 | 0.040 |
Why?
|
| Protein Stability | 1 | 2017 | 90 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 132 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2016 | 66 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1998 | 453 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 213 | 0.030 |
Why?
|
| Suppuration | 1 | 1996 | 3 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1996 | 86 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 119 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 153 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 1993 | 236 | 0.030 |
Why?
|
| Specimen Handling | 1 | 1996 | 47 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 77 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 226 | 0.030 |
Why?
|
| Perfusion | 1 | 1996 | 131 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 7 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2016 | 114 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1996 | 260 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2019 | 337 | 0.030 |
Why?
|
| Fasting | 1 | 2015 | 75 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 87 | 0.030 |
Why?
|
| NF-kappa B | 1 | 1998 | 432 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 260 | 0.030 |
Why?
|
| Antioxidants | 1 | 1998 | 304 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 114 | 0.030 |
Why?
|
| Diet | 1 | 1999 | 514 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 274 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 499 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2015 | 200 | 0.030 |
Why?
|
| Drainage | 1 | 1996 | 133 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1995 | 14 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 562 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 196 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 35 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 42 | 0.030 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 1995 | 17 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 276 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 1995 | 99 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1995 | 35 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 714 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 193 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 89 | 0.030 |
Why?
|
| Calcium | 2 | 2015 | 929 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 92 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2018 | 254 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 71 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 274 | 0.030 |
Why?
|
| Arginine | 1 | 1995 | 102 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2014 | 155 | 0.030 |
Why?
|
| Lebanon | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proteins | 1 | 2018 | 474 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 120 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 800 | 0.030 |
Why?
|
| Mitochondria | 1 | 2019 | 643 | 0.030 |
Why?
|
| Cytochalasin B | 1 | 1993 | 7 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 420 | 0.030 |
Why?
|
| Glutathione | 1 | 2016 | 343 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1993 | 45 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2013 | 21 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 164 | 0.030 |
Why?
|
| Serotonin | 1 | 1993 | 144 | 0.030 |
Why?
|
| Thrombin | 1 | 1993 | 117 | 0.030 |
Why?
|
| Clinical Medicine | 1 | 2013 | 20 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 1047 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 331 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 60 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 161 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 2013 | 77 | 0.030 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 1992 | 6 | 0.030 |
Why?
|
| Societies | 1 | 2011 | 15 | 0.030 |
Why?
|
| Cell Survival | 1 | 2014 | 901 | 0.020 |
Why?
|
| Pancreatic Pseudocyst | 1 | 1990 | 24 | 0.020 |
Why?
|
| Bile | 1 | 2010 | 35 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 69 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 59 | 0.020 |
Why?
|
| Epithelium | 1 | 2010 | 172 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 1990 | 15 | 0.020 |
Why?
|
| Intestinal Fistula | 1 | 1990 | 26 | 0.020 |
Why?
|
| Ceruletide | 1 | 2010 | 8 | 0.020 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2010 | 10 | 0.020 |
Why?
|
| Clotrimazole | 1 | 2009 | 3 | 0.020 |
Why?
|
| Chlorine | 1 | 2010 | 76 | 0.020 |
Why?
|
| Apamin | 1 | 2009 | 13 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 40 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 2009 | 29 | 0.020 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2009 | 10 | 0.020 |
Why?
|
| Buffers | 1 | 2009 | 31 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2009 | 13 | 0.020 |
Why?
|
| Suramin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1990 | 97 | 0.020 |
Why?
|
| Barium | 1 | 2009 | 52 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 2891 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 1990 | 113 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Serum | 1 | 2008 | 24 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 100 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 59 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2008 | 149 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 50 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 55 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 498 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2007 | 13 | 0.020 |
Why?
|
| Ketones | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2007 | 35 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2007 | 62 | 0.020 |
Why?
|
| Colitis, Ischemic | 1 | 2005 | 2 | 0.020 |
Why?
|
| Diverticulum, Colon | 1 | 2005 | 3 | 0.020 |
Why?
|
| Telangiectasis | 1 | 2005 | 6 | 0.020 |
Why?
|
| Emergencies | 1 | 2005 | 107 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2008 | 322 | 0.020 |
Why?
|
| Weight Loss | 1 | 2007 | 319 | 0.010 |
Why?
|
| Advisory Committees | 1 | 2004 | 73 | 0.010 |
Why?
|
| Alcoholism | 1 | 1992 | 1109 | 0.010 |
Why?
|
| Critical Care | 1 | 2005 | 263 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 742 | 0.010 |
Why?
|
| Receptors, Leptin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 92 | 0.010 |
Why?
|
| Thinness | 1 | 2002 | 14 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2002 | 86 | 0.010 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2000 | 2 | 0.010 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2000 | 12 | 0.010 |
Why?
|
| Esterification | 1 | 2000 | 25 | 0.010 |
Why?
|
| Retinol-Binding Proteins | 1 | 2000 | 28 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 189 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2000 | 62 | 0.010 |
Why?
|
| Hyperlipoproteinemias | 1 | 1999 | 2 | 0.010 |
Why?
|
| Endotoxemia | 1 | 1999 | 27 | 0.010 |
Why?
|
| Fructose | 1 | 1999 | 51 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 597 | 0.010 |
Why?
|
| Triglycerides | 1 | 1999 | 184 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1999 | 161 | 0.010 |
Why?
|
| Integrin alpha2 | 1 | 1997 | 4 | 0.010 |
Why?
|
| Integrin alpha1 | 1 | 1997 | 5 | 0.010 |
Why?
|
| Integrin alpha1beta1 | 1 | 1997 | 5 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 700 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1997 | 199 | 0.010 |
Why?
|
| Duodenum | 1 | 1995 | 47 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1995 | 89 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1995 | 89 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1995 | 66 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1994 | 282 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1994 | 220 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 1083 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1992 | 13 | 0.010 |
Why?
|